相关实验视频

Updated: Jun 20, 2026

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

在接受新辅助治疗的患者中,ctDNA检测和复发评估的关联

Jiaxin Zhou^1,2, Haocong Mo³, Dahai Hu¹

¹General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Cancer medicine

|September 25, 2023

概括

在新辅助治疗后检测循环瘤DNA (ctDNA) 表明癌症复发的风险更高. 这一发现支持ctDNA的发现.

科学领域:

在瘤学瘤学.
分子诊断学分子诊断学
癌症生物标志物癌症生物标志物

背景情况:

新辅助疗法的使用正在增加,但缺乏治疗反应的验证生物标志物.
循环瘤DNA (ctDNA) 检测是一种新兴的监测工具,在瘤学中具有预后潜力.
在新辅助疗法后准确预测癌症复发仍然是一个临床挑战.

研究的目的:

研究ctDNA检测作为接受新辅助治疗的患者癌症复发的预测生物标志物的临床意义.
评估ctDNA阳性与不同癌症类型癌症复发风险之间的关联.

主要方法:

一项系统的文献搜索发现了与癌症复发后新辅助疗法相关联的ctDNA检测研究.
分析计算出癌症复发的危险比率 (HRs) 和95%置信区间 (95%CI).
癌症复发是主要的结局指标.

主要成果:

分析了23项研究,包括8种癌症类型的1590名患者.
阳性ctDNA检测与癌症复发的增加显著相关,特别是在新辅助治疗和手术后.
复发风险因癌症类型,检测时间和地理区域而异.

结论:

在接受新辅助治疗的患者中,ctDNA检测是癌症复发风险较高的显著积极预测指标.
癌症类型,检测时间和地理位置都会影响复发风险.
作为预后标志物和监测工具,ctDNA显得有前途,但需要进一步研究以阐明机制.

关键词:

生物标志物生物标志物癌症癌症癌症癌症癌症在循环中的瘤DNA.进行元分析.这是新辅助治疗.

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

相关概念视频

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...